Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastrointestinal Diseases: early-phase trial registry
8 of 15 indexed Gastrointestinal Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 8 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Gastrointestinal Diseases: 15 US clinical trials tracked, 8 recruiting.
Gastrointestinal Diseases is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 2 of these trials.
Enrollment posture brief
Registry condition gastrointestinal-diseases
OPEN 8 | RECR 53% | LATE 1 | EARLY 2 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Beta-Thalassemia (53% recruiting · 15 trials)
Gastrointestinal Diseases lists 8 open slots (53% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastrointestinal Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastrointestinal Diseases is recruiting above its size-band peers.
8 of 15 indexed trials (53.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastrointestinal Diseases trials is spread across many organizations.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 2 of 15 trials (13.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastrointestinal Diseases enrolment sits around 278 participants.
Median target enrolment is 278 among the 15 trials that report a genuine target (sentinel values excluded). 4 of those (26.7%) plan for fewer than 100 participants.
-
Gastrointestinal Diseases research is mostly interventional.
11 interventional and 4 observational studies make up this index (73.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Evaluation of Patients With Gastrointestinal Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05041374
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
NCT07222800
Immune Responses to Gluten
Boston Children's Hospital
NCT05209568
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
NCT05489237
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
Medtronic - MITG
NCT07351071
Trans-nasal Endoscopy for Bariatric Patients
Christopher C. Thompson, MD, MSc
NCT06200961
Foregut Leaks-Role of Microbiome
Baylor Research Institute
NCT07424469
Virtual Reality for Non-cardiac Chest Pain
Mayo Clinic
NCT06262126
An Observational Study of Patients With Chronic Gastrointestinal Disease
Target PharmaSolutions
NCT05774080
Evaluation of People With Gastrointestinal Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01639924
A Trial of Tap Water Treatment in the Elderly
National Institute on Aging (NIA)
NCT00058942
A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program
Boston Children's Hospital
NCT00514670
A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
The SmartPill Corporation
NCT00128284
Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)
Tsumura U
NCT01890837
Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Boston University
NCT01910792
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastrointestinal Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastrointestinal Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastrointestinal Diseases page
15 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Gastrointestinal Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors the most Gastrointestinal Diseases trials on record, review their full trial history before evaluating a specific study. See National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastrointestinal Diseases condition card totals 15 registered trials; most-linked intervention Sperti Lamp; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.